Cancer, Rare Disease Drugs To Be Covered As China Expands Reimbursement

Pharmaceuticals that have gained approvals before Dec. 31, 2018 will be subject to consideration for a new expansion of China's National Reimbursement Drug List (NRDL), with priority to be given to national essential drugs, cancer and rare disease medicines, treatments for chronic disorders, pediatric medications and urgent care products.

Outlined in the 2019 National Healthcare Product coverage adjustment work plans, released by the country's Medical Insurance and Support Administration (MISA), the reimbursement of the